Whitebox Advisors LLC Decreases Stock Holdings in Grifols, S.A. (NASDAQ:GRFS)

Whitebox Advisors LLC decreased its holdings in shares of Grifols, S.A. (NASDAQ:GRFS - Free Report) by 6.5% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 3,947,631 shares of the biotechnology company's stock after selling 273,852 shares during the quarter. Grifols comprises 0.9% of Whitebox Advisors LLC's holdings, making the stock its 29th largest holding. Whitebox Advisors LLC owned approximately 0.57% of Grifols worth $29,370,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in GRFS. Jane Street Group LLC lifted its holdings in shares of Grifols by 87.9% in the 4th quarter. Jane Street Group LLC now owns 76,729 shares of the biotechnology company's stock worth $571,000 after acquiring an additional 35,901 shares during the last quarter. Boothbay Fund Management LLC acquired a new position in Grifols during the fourth quarter worth $140,000. Credit Industriel ET Commercial acquired a new position in Grifols during the fourth quarter worth $4,537,000. Cigogne Management SA purchased a new position in shares of Grifols during the fourth quarter worth $1,778,000. Finally, Syon Capital LLC acquired a new stake in shares of Grifols in the fourth quarter valued at $197,000.

Grifols Stock Up 4.7 %

Shares of GRFS traded up $0.33 during mid-day trading on Friday, hitting $7.35. 543,821 shares of the company's stock were exchanged, compared to its average volume of 1,196,636. The company has a debt-to-equity ratio of 1.11, a quick ratio of 0.79 and a current ratio of 2.26. The company has a market cap of $5.05 billion, a price-to-earnings ratio of 6.28 and a beta of 0.44. The stock's 50-day moving average is $7.44 and its 200-day moving average is $7.70. Grifols, S.A. has a fifty-two week low of $5.79 and a fifty-two week high of $9.96.

Wall Street Analyst Weigh In

Separately, Morgan Stanley started coverage on Grifols in a research note on Wednesday, February 12th. They set an "overweight" rating on the stock.

About Grifols

Grifols, SA operates as a plasma therapeutic company in Spain, the United States, Canada, and internationally. The company provides immunoglobulin to treat immunodeficiencies; albumin used to restore circulatory volume and protein loss in pathophysiological conditions, such as liver cirrhosis, cardiocirculatory failure, trauma and severe burns; alpha-1 proteinase inhibitor, a plasma protein, used to treat a genetic disease known as alpha-1; factorVIII/von Willerbrand factor and factor IX, clotting factors for the treatment of hemophilia A and von Willebrand's disease, as well as hemophilia B; antithrombin III to treat hereditary antithrombin deficiency; Fostamatinib, a spleen tyrosine kinase inhibitor; combination of fibrinogen and enzyme thrombin that acts as a biological sealant to control surgical bleeding; and plasma exchange with albumin used to treat Alzheimer's disease.